N-Acetylgalactosamine 6-sulfate | 10357-00-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-Acetylgalactosamine 6-sulfate
• 英文别名: [(2R,3R,4R,5R)-5-acetamido-2,3,4-trihydroxy-6-oxohexyl] hydrogen sulfate
• CAS: 10357-00-3
• 化学式: C₈H₁₅NO₉S
• 分子量: 301.27
• InChiKey: NHZWETQZLORZIR-OSMVPFSASA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  179
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolitic products
  申请人：——

  公开号：US20030228259A1

  公开（公告）日：2003-12-11

  Methods of determining rate of biosynthesis or breakdown of biological molecules from metabolic derivatives and catabolic products are disclosed herein. In particular, methods of measuring the rates of biosynthesis and breakdown of biological molecules inaccessible or not easily accessible to direct sampling by sampling metabolic derivatives and catabolic products in accessible biological samples are disclosed herein.

  本发明公开了确定生物分子生物合成或分解速率的方法，具体为通过取样可获取的生物样本中的代谢衍生物和分解产物，测量难以或不易直接取样的生物分子的生物合成和分解速率。
• Oligosaccharide biomarkers for mucopolysaccharidoses and other related disorders
  申请人：Meikle John Peter

  公开号：US20060286034A1

  公开（公告）日：2006-12-21

  The present invention is related to methods for diagnosing mucopolysaccharidoses (“MPS”) and related diseases. This invention pertains to methods for identifying and quantitating biochemical markers (“biomarkers”) that are present in biological fluids or tissues of a patient having a MPS or related disorder. One aspect of the method comprises determining a target quantity of a target MPS biomarker oligosaccharide from a target biological sample taken from the target animal, and then comparing the target quantity to a reference quantity of a reference MPS biomarker oligosaccharide for the diagnosis, characterization, monitoring, and clinical management of MPS and related disease. This invention also describes a kit comprising a oligosaccharide derivatization solution; an acid solution; an internal standard; a solid phase extraction column; a solid phase extraction column wash solution; an oligosaccharide elution solution; and a set of instructions for using the kit to diagnose a MPS or related disease.

  本发明涉及诊断粘多糖病（“MPS”）及相关疾病的方法。本发明涉及一种用于识别和定量生物标志物（“生物标记物”）的方法，这些生物标记物存在于患有MPS或相关疾病的患者的生物体液或组织中。该方法的一个方面包括确定来自目标生物样本的目标动物的目标MPS生物标记物寡糖的目标量，然后将目标量与用于诊断、表征、监测和临床管理MPS和相关疾病的参考MPS生物标记物寡糖的参考量进行比较。本发明还描述了一种工具包，包括寡糖衍生物溶液；酸溶液；内部标准；固相萃取柱；固相萃取柱洗涤溶液；寡糖洗脱溶液；以及一套用于使用该工具包诊断MPS或相关疾病的说明书。
• [EN] POLYMERIC CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS POLYMÈRES ET LEURS UTILISATIONS
  申请人：FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIG PRINCIPE FELIPE

  公开号：WO2020193802A1

  公开（公告）日：2020-10-01

  The present invention relates to novel chemical entities comprising a polymeric carrier incorporating covalently linked drug(s) as well as their pharmaceutical compositions containing the said polymer-drug conjugates as pharmaceutical agents and their uses thereof in therapy and, more particularly, but not exclusively, to novel conjugates having attached thereto a targeting moiety, an imaging agent and one or more therapeutic agents to promote axonal growth and for the treatment of neurodegenerative and inflammatory diseases, central nervous system traumatic injuries and cancer.

  本发明涉及一种新型化学实体，包括将药物共价连接到聚合载体中的药物，以及包含所述聚合物-药物共轭物作为药物代理的药物组合物，以及它们在治疗中的用途，更具体地说，但不限于，涉及附有靶向基团、成像剂和一个或多个治疗剂的新型共轭物，用于促进轴突生长和治疗神经退行性和炎症性疾病、中枢神经系统创伤性损伤和癌症。
• Methods For Treating A Condition Characterized By Dysfunction In Protein Homeostasis
  申请人：Segatori Laura

  公开号：US20090203605A1

  公开（公告）日：2009-08-13

  Methods are provided for treating conditions characterized by dysfunction in protein homeostasis in a patient in need thereof. A method for treating a condition characterized by dysfunction in protein homeostasis in a patient in need thereof is provided which comprises administering to the patient a proteostasis regulator in an amount effective to improve or restore protein homeostasis, and to reduce or eliminate the condition in the patient or to prevent its occurrence or recurrence. The condition can be a loss of function disorder such as a lysosomal storage disease, or a gain of function disorder such as an aging associated disease.

  提供了一种用于治疗患有蛋白质稳态功能障碍的患者的方法。提供了一种治疗患有蛋白质稳态功能障碍的患者的方法，包括向患者施用一种蛋白稳态调节剂，其有效量能够改善或恢复蛋白质稳态，并减少或消除患者的疾病，或预防其发生或复发。该疾病可以是功能丧失性疾病，如溶酶体贮积病，或功能增强性疾病，如与衰老相关的疾病。
• Targeting of glycoprotein therapeutics
  申请人：Stefano James

  公开号：US20060228348A1

  公开（公告）日：2006-10-12

  Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.

  本文描述了制备治疗性糖蛋白的配体修饰聚合物共轭物的方法。通过使用高分子量聚合物（例如PEG、多唾液酸等）来掩盖天然糖类和其他表面决定因子，并将其装饰上靶向特定组织的配体，从而实现了对糖蛋白的改进靶向。在某些实施例中，这种共轭物中的酸敏感连接或快速可降解的掩蔽基团允许在溶酶体中发现的条件下从糖蛋白中释放聚合物。